Hubei Biocause Heilen Pharmaceutical Co., Ltd.
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Hubei Hengdi Pharmaceutical Co., Ltd. was listed on the Shenzhen Stock Exchange Growth Enterprise Board (stock code: 301211) on December 22, 2021, and was established in 1995. Mainly engaged in the research and development, production, and sales of pharmaceutical raw materials and preparation products. The registration and production base are located in Jingmen, Hubei, and the research and development and sales center is located in Wuhan. The company has three subsidiaries: Wuhan Baike Pharmaceutical Development Co., Ltd., Wuhan Hengdi Pharmaceutical Development Co., Ltd., and Hubei Baike Pharmaceutical Trading Co., Ltd., and one branch: Hubei Hengdi Pharmaceutical Co., Ltd. Research Institute Branch. The company is a postdoctoral pharmaceutical industry base in Hubei Province, a high-tech enterprise in Hubei Province, a pharmaceutical teaching base of Tongji Medical College of Huazhong University of Science and Technology, the fourth batch of recessive champion enterprises in Hubei Province, one of the six key suppliers of COVID-19 epidemic prevention in Hubei Province in 2020, and one of the six major manufacturers of ibuprofen APIs in the world. It is a leading enterprise of global non steroidal anti-inflammatory APIs. The company has over 50 varieties of pharmaceutical raw materials and preparations, making it an important base for antipyretic and analgesic raw materials in China, a base for anti-tumor characteristic raw materials in Hubei Province, and a solid preparation manufacturing base. Its product customers are located in over 80 countries and regions around the world. The company currently has 8 Chinese invention patents and 1 foreign invention patent, with a total of more than ten varieties registered in nearly 20 countries in Europe and America. The Jingmen and Wuhan bases have passed multiple inspections and certifications by the European and American Drug Administration, making them one of the few enterprises in China that have passed both European and American GMP certification inspections. After years of development, the company has achieved rich technological achievements and formed independent patented technologies through independent innovation, Equipped with industry-leading production and processing techniques, it has gained widespread recognition in the industry and market. In the future, the company will take the opportunity of stock listing, adhere to the business philosophy of "scientific enterprise, healthy life", adhere to the principle of raw materials drugs as the main focus, and strive to build an important production base for non-steroidal anti-inflammatory raw materials, characteristic raw materials, and formulations in China, achieve collaborative development of raw materials and formulations, further explore the business layout of CDMO, and aspire to become a leading domestic and world-class pharmaceutical enterprise. |
| Headquarter | Jingmen |
| Establish Date | 12/29/1995 |
| Listed Code | 301211.SZ |
| Listed Date | 12/22/2021 |
| Chairman | Cheng Zhigang. |
| CEO | Liang Qun. |
| Website | www.biocause.com |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
